Factors affecting the incidence Stenotrophomonas maltophilia isolation in cystic fibrosis

被引:59
作者
Graff, GR
Burns, JL
机构
[1] Univ Missouri, Dept Child Hlth, Columbia, MO 65212 USA
[2] Childrens Hosp, Div Infect Dis, Seattle, WA USA
[3] Reg Med Ctr, Seattle, WA USA
关键词
cystic fibrosis; quinolone; Stenotrophomonas maltophilia; steroids; tobramycin;
D O I
10.1378/chest.121.6.1754
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: To identify factors predisposing cystic fibrosis (CF) patients to Stenotrophomonas maltophilia infection and to determine whether coinfection with S maltophilia affects the clinical response to therapy with tobramycin solution for inhalation (TSI), 300 mg bid. Design: Retrospective review of data collected from two identical, 6-month, randomized, placebo-controlled trials. Setting: Sixty-nine CF centers in the United States. Interventions: Active drug administration of 300 mg TSI. Patients: Five hundred twenty CF patients with chronic Pseudomonas aeruginosa endobronchial infections. Measurements and results: A logistic regression analysis identified factors contributing to increased S maltophilia isolation frequency. In this multivariate analysis, the only significant predictors of S maltophilia isolation during the last month of the trial were the concomitant use of oral quinolones (primarily ciprofloxacin; p = 0.0015) and S maltophilia isolation prior to treatment (p < 0.0001). Treatment group, gender, age, use of systemic or inhaled steroids, use of oral sulfonamide, IV cephalosporins, or penicillin antibiotics, baseline FEV1 percent predicted, and pretreatment Aspergillus isolation were not significant predictors of subsequent S maltophilia infection. In addition, S maltophilia-positive culture frequency was compared to the change in pulmonary function. Patients who either never had culture results positive for S maltophilia or who were positive at <25% of observations had greater clinical response to TSI at the final study visit compared to patients who were positive at greater than or equal to25% of observations. Conclusions: TSI therapy did not result in a greater risk for isolation of S maltophilia than standard care alone. In contrast, oral quinolone antibiotic use during the trial was associated with a 2.7-fold increased risk of having a culture positive for S maltophilia (p = 0.0015). The use of TSI to suppress P aeruginosa resulted in improved lung function, regardless of S maltophilia culture frequency. However, improvement was not as great among patients who were persistently coinfected with S maltophilia.
引用
收藏
页码:1754 / 1760
页数:7
相关论文
共 21 条
[1]   STENOTROPHOMONAS MALTOPHILIA IN CYSTIC-FIBROSIS PATIENTS [J].
BALLESTERO, S ;
VIRSEDA, I ;
ESCOBAR, H ;
SUAREZ, L ;
BAQUERO, F .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (08) :728-729
[2]   PSEUDOMONAS-AERUGINOSA CORNEAL ULCER ISOLATES DISTINGUISHED USING THE ARBITRARILY PRIMED PCR DNA-FINGERPRINTING METHOD [J].
BUKANOV, N ;
RAVI, VN ;
MILLER, D ;
SRIVASTAVA, K ;
BERG, DE .
CURRENT EYE RESEARCH, 1994, 13 (11) :783-790
[3]   Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis [J].
Burns, JL ;
Van Dalfsen, JM ;
Shawar, RM ;
Otto, KL ;
Garber, RL ;
Quan, JM ;
Montgomery, AB ;
Albers, GM ;
Ramsey, BW ;
Smith, AL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (05) :1190-1196
[4]   Microbiology of sputum from patients at cystic fibrosis centers in the United States [J].
Burns, JL ;
Emerson, J ;
Stapp, JR ;
Yim, DL ;
Krzewinski, J ;
Louden, L ;
Ramsey, BW ;
Clausen, CR .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (01) :158-163
[5]  
Cystic Fibrosis Foundation, 2000, PAT REG 1999 ANN DAT
[6]  
Demko CA, 1998, PEDIATR PULM, V25, P304, DOI 10.1002/(SICI)1099-0496(199805)25:5<304::AID-PPUL3>3.3.CO
[7]  
2-K
[8]   Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients [J].
Denton, M ;
Todd, NJ ;
Littlewood, JM .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (05) :402-405
[9]  
ELTING LS, 1990, INFECT CONT HOSP EP, V11, P134